The prescription pattern of first-line anti-hypertensives among family medicine trainees in Hong Kong part 1: In the absence of concomitant cardiovascular risk factors

Hong Kong Practitioner

Volumn 26, Issue 10, 2004, Pages 420-429

  Wong, M C S ^a,c   Chung, R Y ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Lek Yuen Health Centre   (Hong Kong)

Author keywords

Anti hypertensives; Family practice; First line; Prescription

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; INDAPAMIDE; LISINOPRIL; METHYLDOPA; METOPROLOL; NIFEDIPINE; PERINDOPRIL; THIAZIDE DIURETIC AGENT;

AGE DISTRIBUTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FAMILY MEDICINE; GENERAL PRACTITIONER; HONG KONG; HUMAN; HYPERTENSION; INTERVIEW; MEDICAL DECISION MAKING; MEDICAL EDUCATION; META ANALYSIS; MOTIVATION; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; SEX DIFFERENCE; SYSTEMATIC REVIEW; TELEPHONE; TIME;

EID: 10944274179     PISSN: 10273948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Singh RB, Suh IL, Singh VP, et al. Hypertension and stroke in Asia: Prevalence, control and strategies in developing countries for prevention. J Hum Hypertens 2000; 14:749-763.
2. Lau GS, Chan JC, Chu PL, et al. Use of antidiabetic and antihypertensive drugs in hospital and outpatient settings in Hong Kong. Ann Pharmacother 1996;30:232-237.
3. Messerli HF, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?: A systematic review. JAMA 1998;279:1903-1907.
4. Wright JM, Lee CH, Chambers GH. Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug? CMAJ 1999; 161:25-32.
5. Cheng A. Hypertension guidelines: JNC 7 versus ESC recommendations. Commentary, Medical Tribune, December 2003.
6. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
7. Calvo CB, Rubinstein A. Influence of new evidence on prescription patterns. J Am Board Fam Pract 2002; 15:457-462.
8. Bog-Hansen E, Lindblad U, Ranstam J, et al. Antihypertensive drug treatment in a Swedish community: Skrarborg hypertension and diabetes project. Pharmacoepidemiology and Drug Safety 2002;11:45-54.
9. Campbell NRC, McAlister FA, Brant R, et al. Temporal trends in antihypertensive drug prescriptions in Canada before and after introduction of the Canadian Hypertension Education Programme. J Hypertens 2003; 21:1591-1597.
10. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. [Miscellaneous Article] J Hypertens 1999;17:151-183.
11. Hypertension Management Guide for Doctors. National Heart Foundation of Australia 2004;12:17.
12. British Hypertension Society guidelines for hypertension management. BMJ 1999;319:630-635.
13. The Seventh Report of the Joint National Committee (JNC) on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. US Department of Health and Human Services, May 2003.
14. Annual Report 2002-2003, pp.18-23. The Hong Kong College of Family Physicians. Submitted by the Honorary Secretary at the HKCFP Annual General Meeting on 12th December, 2003
15. Psaty BM, Manolio TA, Smith NL, et al. Time trends in high blood pressure control and the use of anti-hypertensive medications in older adults: The Cardiovascular Health Study. Arch Intern Med 2002; 162:2325-2332.
16. Bakris GL, Willaims M, Dworkin L, et al for the National Kidney Foundation Hypertesnion and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36:646-661.
17. Lewis EJ, Hunsicker LG, Clarke WR, et al for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
18. Williams B. Drug Treatment of hypertension (Editorials). BMJ 2003;326: 61-62.
19. Wong BL. Hypertension - A Guide to Clinical Practice. The Hong Kong Medical Association CME Bulletin, January 2004.
20. Murtagh J. General Practice. 2nd edition. pp.1082 The McGraw-Hill Companies, Inc 1999.
21. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657-1664.
22. Shulman N, Cutter G, Daugherty R, et al. Correlates of attendance and compliance in the hypertension detection and follow-up programme. Control Clin Trials 1982;3:13-27.
23. Black DM, Brand RJ, Greenlick M, et al for the SHEP Pilot Research Group. Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. J Gerontol 1987;42:552-557.
24. Neaton JD, Grimm RH Jr, Prineas RJ, et al for the Treatment of Mild Hypertension Study Research Group. Treatment of mild hypertension: final results. JAMA 1993;270:713-724.
25. HDFP Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality in persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-2571.
26. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991;265:3255-3264.
27. Jones JK, Gorkin L, Lian F, et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995;311:293-295.